Results 71 to 80 of about 3,679,356 (272)

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Clinical Cancer Research, 2021
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for myelodysplastic syndromes and acute myelogenous leukemias.
P. Zavras, A. Shastri, M. Goldfinger, Amit Verma, Y. Saunthararajah   +4 more
semanticscholar   +1 more source

Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong

Therapeutic Advances in Hematology
Background: The pivotal trial on venetoclax and hypomethylating agents in unfit elderly acute myeloid leukaemia (AML) has got FDA approval. However, Asian patients were under-represented and showed no survival advantage.
Qiwen Fang, Chi Yeung Fung, Jiaqi Wang, Wing Hei Lai, Raymond S. M. Wong, Bonnie C. S. Kho, June S. M. Lau, Vivien W. M. Mak, Chung Yin Ha, Xue Li, Anskar Yu-Hung Leung   +10 more
doaj   +1 more source

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. [PDF]

, 2015
BackgroundDemethylation process is necessary for the expression of various factors involved in chemotherapy cytotoxicity or resistance. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1.
Culotta, Kirk, Falchook, Gerald, Fu, Siqing, He, Guangan, Hess, Kenneth, Issa, Jean-Pierre J, Jelinek, Jaroslav, Kurzrock, Razelle, Naing, Aung, Piha-Paul, Sarina, Said, Rabih, Siddik, Zahid H, Stewart, David J, Tsimberidou, Apostolia M, Wistuba, Ignacio, Zinner, Ralph   +15 more
core   +2 more sources

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood Cancer Journal
Dear Editor, TP53 is a tumor suppressor gene located on the short arm of chromosome 17(p13), known to be involved in multiple cellular processes and regulate cell proliferation by responding to various stress [1, 2]. TP53 is a frequently mutated (m) gene
T. Badar, Ahmad Nanaa, E. Atallah, R. Shallis, Sacchi de Camargo Correia Guilherme, A. Goldberg, Antoine N. Saliba, A. Patel, J. Bewersdorf, A. Duvall, Danielle Bradshaw, Y. Abaza, G. Murthy, N. Palmisiano, A. Zeidan, Vamsi K Kota, M. Litzow   +16 more
semanticscholar   +1 more source

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

Frontiers in Oncology, 2021
The nucleoside analogs decitabine (5-AZA-dC) and azacitidine (5-AZA) have been developed as targeted therapies to reverse DNA methylation in different cancer types, and they significantly improve the survival of patients who are not suitable for ...
Guangjie Zhao, Qian Wang, Shuang Li, Xiaoqin Wang   +3 more
semanticscholar   +1 more source

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Dasatinib and azacitidine followed by haploidentical stem cell transplant for chronic myeloid leukemia with evolving myelodysplasia: A case report and review of treatment options. [PDF]

, 2017
BACKGROUND: CML presenting with a variant Philadelphia translocation, atypical BCR-ABL transcript, additional chromosomal aberrations, and evolving MDS is uncommon and therapeutically challenging.
Ottmann, Oliver
core   +2 more sources

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

A critical role of epigenetic inactivation of miR-9 in EVI1high pediatric AML

Molecular Cancer, 2019
Ectopic Viral Integration site 1 (EVI1) upregulation is implicated in 10–25% of pediatric acute myeloid leukemia (AML) and has an inferior outcome with current chemotherapy regimens. Here we report that EVI1 upregulation is associated with methylation of
Nupur Mittal, Liping Li, Yue Sheng, Chao Hu, Fuxing Li, Tongyu Zhu, Xiaohong Qiao, Zhijian Qian   +7 more
doaj   +1 more source

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia

Clinical and Translational Science, 2021
Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event‐free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog ...
Daelynn R. Buelow, Jason T. Anderson, Stanley B. Pounds, Lei Shi, Jatinder K. Lamba, Shuiying Hu, Alice A. Gibson, Emily A. Goodwin, Alex Sparreboom, Sharyn D. Baker   +9 more
doaj   +1 more source